Research Progress in Immune Checkpoint Inhibitors for Relapsed and Refractory Malignant Gonadal Germ Cell Tumors.
10.3881/j.issn.1000-503X.16055
- Author:
Tian-Yu ZHANG
1
;
Jia-Xin YANG
1
Author Information
1. Department of Obstetrics and Gynecology,National Clinical Research Center for Obstetrics and Gynecology, PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
- Publication Type:Review
- Keywords:
clinical trial;
immune checkpoint inhibitor;
malignant germ cell tumor;
tumor microenvironment
- MeSH:
Humans;
Neoplasms, Germ Cell and Embryonal/therapy*;
Immune Checkpoint Inhibitors/therapeutic use*;
Immunotherapy;
Testicular Neoplasms/drug therapy*;
Neoplasm Recurrence, Local;
Drug Resistance, Neoplasm
- From:
Acta Academiae Medicinae Sinicae
2025;47(1):131-136
- CountryChina
- Language:English
-
Abstract:
Germ cell tumors typically occur in the gonadal regions,characterized by high malignancy and rapid progression.Due to their high sensitivity to chemotherapy,the cure rate is generally high.However,a portion of patients still succumb to chemotherapy resistance and disease progression.The use of immune checkpoint inhibitors has significantly improved the prognosis for various solid tumors,while the immune mechanisms and efficacy of immunotherapy in germ cell tumors remain understudied.Whether relapsed and refractory germ cell tumors can benefit from immune checkpoint inhibitors remains to be investigated.In this review,we summarize the immune-related mechanisms,case reports,and clinical trials of immunotherapy in germ cell tumors to assess the effectiveness of this therapy,providing a reference for future basic research and clinical practice.
